Joinn Laboratories (06127): Abnormal fluctuations in A-share stock trading, no significant information that should be disclosed but has not been disclosed.

Joinn Laboratories (06127) announced that the closing price of its A shares had deviated by more than 20% for three consecutive trading days on September 11, 12, and 15, 2025. This constitutes abnormal fluctuations in stock trading according to the relevant rules of the Shanghai Stock Exchange. In response to the abnormal fluctuations in stock trading, the company conducted a check on the relevant matters. The following is an explanation of the situation: (1) Production and Operation Situation Upon self-inspection, the company's production and operation activities are normal at present, and there have been no significant changes in the internal and external operating environment that would impact the abnormal fluctuations in the company's stock trading price. (2) Major Events After self-inspection by the company and written consultation with the controlling shareholder and actual controller, as of the date of this announcement, there are no major events that would affect the abnormal fluctuations in the company's stock trading price. There are no major undisclosed information that should have been disclosed, including but not limited to major asset restructuring, issuance of shares, acquisition of listed companies, debt restructuring, asset disposal, or asset injection. (3) Media Reports, Market Rumors, and Hot Topics The company has not found any media reports or market rumors that require clarification or response. The company has not found any other major events that could have a significant impact on the company's stock price. (4) Other Price-Sensitive Information Upon verification by the company, there is no evidence of the controlling shareholder, actual controller, directors, supervisors, or senior management buying or selling company stocks during the period of abnormal fluctuations in stock trading.